Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$2.92
+2.1%
$2.21
$0.80
$2.98
$751.14M0.882.91 million shs3.96 million shs
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
$2.50
$2.71
$2.07
$4.20
$80.49M0.4389,620 shs115,440 shs
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.36
+12.4%
$0.33
$0.22
$5.36
$14.96M-0.472.80 million shs1.63 million shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.41
+2.1%
$4.39
$3.55
$16.11
$199.70M0.53311,911 shs181,552 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
+2.10%0.00%+22.69%+62.22%+165.45%
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
0.00%-4.21%-9.42%-18.03%+3.31%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
+12.36%+9.86%-2.41%-18.20%-92.87%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
+2.08%+4.26%+7.56%-19.96%-63.91%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4.1765 of 5 stars
4.62.00.04.02.80.00.6
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
2.1088 of 5 stars
3.63.00.00.02.21.70.0
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.9178 of 5 stars
0.05.00.00.02.71.71.3
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
3.4713 of 5 stars
4.41.00.00.03.14.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.20
Buy$6.63126.88% Upside
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
3.25
Buy$9.00260.00% Upside
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00
N/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$16.60276.42% Upside

Current Analyst Ratings Breakdown

Latest YMAB, AKBA, ANIX, and PRPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
4/22/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00
4/10/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/4/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.50 ➝ $7.50
4/1/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
3/26/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/25/2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$184.91M4.15N/AN/A($0.16) per share-18.25
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
$210K383.30N/AN/A$0.59 per share4.24
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.85M2.56N/AN/A$2.74 per share0.13
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$88.66M2.25N/AN/A$2.32 per share1.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%8/14/2025 (Estimated)
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$12.55M-$0.39N/AN/AN/A-58.55%-53.29%6/3/2025 (Estimated)
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%8/13/2025 (Estimated)
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$21.43M-$0.64N/AN/AN/A-28.22%-24.61%-18.49%8/11/2025 (Estimated)

Latest YMAB, AKBA, ANIX, and PRPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2025Q2 2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$0.10N/AN/AN/AN/AN/A
5/20/2025Q1 2025
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
5/8/2025Q1 2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million
3/13/2025Q4 2024
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 million
3/11/2025Q1 2025
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
-$0.10-$0.10N/A-$0.10N/AN/A
3/4/2025Q4 2024
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.13-$0.15-$0.02-$0.15$26.70 million$26.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/A
1.52
1.21
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
N/A
8.54
8.54
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.48
1.47
1.33
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
3.92
3.54

Institutional Ownership

CompanyInstitutional Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
29.13%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.00%
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
25.30%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
20.70%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
22.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430262.64 million209.24 millionOptionable
Anixa Biosciences, Inc. stock logo
ANIX
Anixa Biosciences
532.20 million24.05 millionOptionable
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13041.54 million18.93 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million34.71 millionOptionable

Recent News About These Companies

HC Wainwright Brokers Reduce Earnings Estimates for YMAB
YMAB FY2025 EPS Forecast Raised by Cantor Fitzgerald

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$2.92 +0.06 (+2.10%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.92 0.00 (-0.17%)
As of 05/27/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$2.50 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.52 +0.02 (+0.60%)
As of 05/27/2025 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.36 +0.04 (+12.36%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.35 -0.01 (-2.78%)
As of 05/27/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.41 +0.09 (+2.08%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.41 0.00 (0.00%)
As of 05/27/2025 05:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.